Table 1 Maternal and neonatal characteristics
Total | ninfected | |
|---|---|---|
114 | 2 | |
Gestational age at delivery | ||
< 33. + 0 weeks | 1 | 0 |
33. + 0-36. + 6 weeks | 51 | 1 |
≥ 37. + 0 weeks | 62 | 1 |
Maternal HIV-1 RNA at delivery | ||
< 50 | 55 | 0 |
50–2999 | 44 | 1 |
3000 – 10000 | 7 | 0 |
> 10000 | 7 | 1 |
missing viral load at birth | 1 | 0 |
Maternal CD4 cell count at delivery (cells/μl) ( n = 104, missing data n = 10) | ||
< 200 | 11 | 1 |
200 – 349 | 26 | 1 |
≥ 350 | 67 | 0 |
Gender of neonate | ||
female | 66 | 2 |
male | 48 | 0 |
Mode of delivery | ||
elective cesarean | 77 | 2 |
emergency cesarean | 33 | 0 |
vaginal delivery | 4 | 0 |
Initiation of antenatal ART (weeks) (n = 112, missing data n = 2) | ||
none | 3 | 0 |
non-stop from onset | 24 | 1 |
≤ 20 | 15 | 0 |
21 – 28 | 17 | 0 |
> 28 | 53 | 1 |
Last antenatal art (n = 113, missing data n = 1) | ||
HAART | 95 | 2 |
dual-drug therapy | 12 | 0 |
Monotherapy | 3 | 0 |
none | 3 | 0 |
Intrapartum prophylaxis | ||
Yes | 113 | 2 |
No | 1 | 0 |
Duration of postnatal child prophylaxis (weeks) | ||
2 | 74 | 2 |
4 | 8 | 0 |
6 | 32 | 0 |
Postnatal child prophylaxis | ||
dual or HAART | 12 | 0 |
Monotherapy | 102 | 2 |
At-risk-group/risk of infection | ||
low risk | 78 | 1 |
high risk | 26 | 0 |
very high risk | 10 | 1 |
Complete Prophylaxis | ||
Yes | 105 | 1 |
No | 9 | 1 |